Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.67 |
| ▸ | REN | P00797 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | F2 | P00734 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PEPD | P12955 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385014 | 1.00 | ACE (0.67) | ACERENKDM4EF2LMNA | |
| SCHEMBL11212417 | 0.91 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL5556548 | 0.91 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL6783588 | 0.91 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL8094713 | 0.91 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL2443468 | 0.91 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL683117 | 0.91 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL24359898 | 0.88 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL13368120 | 0.88 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL4385020 | 0.88 | ACE (0.70) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629380-B2 | Antitumor agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-08 | — | — | US | disclosed |
| US-7141603-B2 | Antitumor agents | THE REGENTS OF THE UNIVERSITY CALIFORNIA (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050250675-A1 | Antitumor agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-11-10 | — | — | US | disclosed |
| US-6908918-B2 | Antitumor agents | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040034202-A1 | Antitumor agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-02-19 | — | — | US | disclosed |
| EP-1056704-B1 | ANTITUMOR AGENTS | UNIV CALIFORNIA (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6548679-B1 | 5-(Spirocyclopropane)inden-7-one derivative; anticarcinogenic agents for leukemia or lymphoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250675-A1 | Antitumor agents | TP53, RB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACE 3913/4885REN 319/4885KDM4E 2376/4885 |
| US-20040034202-A1 | Antitumor agents | TP53, TPD52L2, RB1 | ACE 3972/4885REN 422/4885KDM4E 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.